Separating therapeutic efficacy from glucocorticoid side-effects in rodent arthritis using novel, liposomal delivery of dexamethasone phosphate: Long-term suppression of arthritis facilitates interval treatment

Arthritis Research and Therapy

Volumn 11, Issue 6, 2009, Pages

  Rauchhaus, Una ^a   Schwaiger, Franz W ^b   Panzner, Steffen ^a  

^a Novosom AG   (Germany)

^b Aurigon Life Science GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; COLLAGEN; CORTICOSTERONE; DEXAMETHASONE SODIUM PHOSPHATE; GLUCOSE; ANTIINFLAMMATORY AGENT; DEXAMETHASONE; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CORTICOSTERONE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LIPOSOMAL DELIVERY; LOW DRUG DOSE; LYMPHOCYTOPENIA; MALE; MOUSE; NEUTROPHILIA; NONHUMAN; PROTEIN DEGRADATION; RAT; SINGLE DRUG DOSE; WEIGHT REDUCTION; ANIMAL; DBA MOUSE; DRUG EFFECT; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; DEXAMETHASONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LIPOSOMES; MALE; MICE; MICE, INBRED DBA; PITUITARY-ADRENAL SYSTEM; RATS; RATS, WISTAR;

EID: 77952539277     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2889     Document Type: Article

References (27)

1. Hopkins RL, Leinung MC. Exogenous Cushing's syndrome and glucocorticoid withdrawal. Endocrinol Metab Clin North Am 2005, 34:371-384. ix, 10.1016/j.ecl.2005.01.013, 15850848.
2. Saklatvala J. Glucocorticoids: do we know how they work?. Arthritis Res 2002, 4:146-150. 10.1186/ar398, 128923, 12010562.
3. Wang M. The role of glucocorticoid action in the pathophysiology of the metabolic syndrome. Nutr Metab (Lond) 2005, 2:3. 10.1186/1743-7075-2-3, 548667, 15689240.
4. Manolagas SC, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 1999, 14:1061-1066. 10.1359/jbmr.1999.14.7.1061, 10404005.
5. Buttgereit F, Wehling M, Burmester GR. A new hypothesis of modular glucocorticoid actions: steroid treatment of rheumatic diseases revisited. Arthritis Rheum 1998, 41:761-767. 10.1002/1529-0131(199805)41:5<761::AID-ART2>3.0.CO;2-M, 9588727.
6. Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 2004, 50:3408-3417. 10.1002/art.20583, 15529366.
7. Song IH, Gold R, Straub RH, Burmester GR, Buttgereit F. New glucocorticoids on the horizon: repress, don't activate!. J Rheumatol 2005, 32:1199-1207.
8. Schacke H, Hennekes H, Schottelius A, Jaroch S, Lehmann M, Schmees N, Rehwinkel H, Asadullah K. SEGRAs: a novel class of anti-inflammatory compounds. Ernst Schering Res Found Workshop 2002, 40:357-371.
9. Avnir Y, Ulmansky R, Wasserman V, Even-Chen S, Broyer M, Barenholz Y, Naparstek Y. Amphipathic weak acid glucocorticoid prodrugs remote-loaded into sterically stabilized nanoliposomes evaluated in arthritic rats and in a Beagle dog: a novel approach to treating autoimmune arthritis. Arthritis Rheum 2008, 58:119-129. 10.1002/art.23230, 18163482.
10. Metselaar JM, Wauben MH, Wagenaar-Hilbers JP, Boerman OC, Storm G. Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum 2003, 48:2059-2066. 10.1002/art.11140, 12847701.
11. Metselaar JM, Berg WB, Holthuysen AE, Wauben MH, Storm G, van Lent PL. Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis. Ann Rheum Dis 2004, 63:348-353. 10.1136/ard.2003.009944, 1754935, 15020326.
12. Schmidt J, Metselaar JM, Wauben MH, Toyka KV, Storm G, Gold R. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain 2003, 126:1895-1904. 10.1093/brain/awg176, 12805101.
13. Barrera P, Mulder S, Smetsers A, Storm G, Beijnen J, Metselaar J, van Riel P. Long-circulating liposomal prednisolone versus pulse intramuscular methylprednisolone in patients with active rheumatoid arthritis [abstract]. Proceedings of the American College of Rheumatology (ACR) Scientific Meeting; Oct 24-29, 2008; San Francisco. Hall A, poster board 453 2008,
14. Ishida T, Ichihara M, Wang X, Yamamoto K, Kimura J, Majima E, Kiwada H. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Control Release 2006, 112:15-25. 10.1016/j.jconrel.2006.01.005, 16515818.
15. Rauchhaus U, Kinne RW, Pohlers D, Wiegand S, Wolfert A, Gajda M, Brauer R, Panzner S. Targeted delivery of liposomal dexamethasone phosphate to the spleen provides a persistent therapeutic effect in rat antigen-induced arthritis. Ann Rheum Dis 2009, 68:1933-1934. 10.1136/ard.2009.108985, 19910302.
16. Olson F, Hunt CA, Szoka FC, Vail WJ, Papahadjopoulos D. Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. Biochim Biophys Acta 1979, 557:9-23. 10.1016/0005-2736(79)90085-3, 95096.
17. Szoka F, Papahadjopoulos D. Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu Rev Biophys Bioeng 1980, 9:467-508. 10.1146/annurev.bb.09.060180.002343, 6994593.
18. Durie FH, Fava RA, Noelle RJ. Collagen-induced arthritis as a model of rheumatoid arthritis. Clin Immunol Immunopathol 1994, 73:11-18. 10.1006/clin.1994.1164, 7923907.
19. Seibel MJ, Woitge H, Scheidt-Nave C, Leidig-Bruckner G, Duncan A, Nicol P, Ziegler R, Robins SP. Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: results of a pilot study. J Bone Miner Res 1994, 9:1433-1440.
20. Kuperman H, Damiani D, Chrousos GP, Dichtchekenian V, Manna TD, Filho VO, Setian N. Evaluation of the hypothalamic-pituitary-adrenal axis in children with leukemia before and after 6 weeks of high-dose glucocorticoid therapy. J Clin Endocrinol Metab 2001, 86:2993-2996. 10.1210/jc.86.7.2993, 11443157.
21. Gaillard RC. Interaction between the hypothalamo-pituitary-adrenal axis and the immunological system. Ann Endocrinol (Paris) 2001, 62:155-163.
22. Claman HN. How corticosteroids work. J Allergy Clin Immunol 1975, 55:145-151. 10.1016/0091-6749(75)90010-X, 803519.
23. Peng CT, Lin HC, Lin YJ, Tsai CH, Yeh TF. Early dexamethasone therapy and blood cell count in preterm infants. Pediatrics 1999, 104:476-481. 10.1542/peds.104.3.476, 10469772.
24. Rooman R, Koster G, Bloemen R, Gresnigt R, van Buul-Offers SC. The effect of dexamethasone on body and organ growth of normal and IGF-II-transgenic mice. J Endocrinol 1999, 163:543-552. 10.1677/joe.0.1630543, 10588828.
25. Rohdewald P, Mollmann H, Barth J, Rehder J, Derendorf H. Pharmacokinetics of dexamethasone and its phosphate ester. Biopharm Drug Dispos 1987, 8:205-212. 10.1002/bdd.2510080302, 3593899.
26. Hatz H. Glukokortikoide. Immunologische Grundlagen, Pharmakologie und Therapierichtlinien 2005, Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 2.
27. Braet F, Wisse E. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol 2002, 1:1. 10.1186/1476-5926-1-1, 131011, 12437787.